Company profile TCRX

Tscan Therapeutics Inc
harnessing novel t cell systems to extend the promise of immunotherapy
Quarter analysis & expected interestLast update: February 09 2024 08:34:18.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
TScan Therapeutics expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
201974
182
145.9% QoQ
351
92.9% QoQ
291
-17.1% QoQ
2020 72
-2.7% YoY -75.3% QoQ
139
-23.6% YoY 93.1% QoQ
195
-44.4% YoY 40.3% QoQ
37
-87.3% YoY -81.0% QoQ
2021 86
19.4% YoY 132.4% QoQ
196
41.0% YoY 127.9% QoQ
351
80.0% YoY 79.1% QoQ
188
408.1% YoY -46.4% QoQ
2022 59
-31.4% YoY -68.6% QoQ
310
58.2% YoY 425.4% QoQ
166
-52.7% YoY -46.5% QoQ
68
-63.8% YoY -59.0% QoQ
2023 255
332.2% YoY 275.0% QoQ
205
-33.9% YoY -19.6% QoQ
197
18.7% YoY -3.9% QoQ
226
232.4% YoY 14.7% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and TScan Therapeutics search interestLast update: February 09 2024 08:34:16.
Correlation coefficient between keyword and revenue is 0.14
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 08:34:18.

The average 5 years interest of TScan Therapeutics was 13.98 per week.
The last year interest of TScan Therapeutics compared to the last 5 years has changed by 11.3%.
This is something to be checked.
The last year interest is comparable to 5 years ago. It has changed only by -9.9%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for T cell receptor-engineered T cell therapies to provide analysis

Correlation between past revenue and T cell receptor-engineered T cell therapies search interest

There is not enough data for T cell receptor-engineered T cell therapies to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for T cell receptor-engineered T cell therapies to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for clinical-stage biopharmaceutical company to provide analysis

Correlation between past revenue and clinical-stage biopharmaceutical company search interest

There is not enough data for clinical-stage biopharmaceutical company to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for clinical-stage biopharmaceutical company to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 08:34:26.

After 39 days of this quarter the interest is at 110.0. Based on that we can calculate that during remaining 52 days it will total up to 257.0.
hematologic malignancies expected interest is significantly lower compared to previous quarter (-50.6%) but similar to same quarter last year.

YearQ1Q2Q3Q4
2019288
443
53.8% QoQ
354
-20.1% QoQ
268
-24.3% QoQ
2020 469
62.8% YoY 75.0% QoQ
212
-52.1% YoY -54.8% QoQ
288
-18.6% YoY 35.8% QoQ
177
-34.0% YoY -38.5% QoQ
2021 254
-45.8% YoY 43.5% QoQ
411
93.9% YoY 61.8% QoQ
562
95.1% YoY 36.7% QoQ
495
179.7% YoY -11.9% QoQ
2022 527
107.5% YoY 6.5% QoQ
297
-27.7% YoY -43.6% QoQ
315
-44.0% YoY 6.1% QoQ
511
3.2% YoY 62.2% QoQ
2023 413
-21.6% YoY -19.2% QoQ
274
-7.7% YoY -33.7% QoQ
434
37.8% YoY 58.4% QoQ
520
1.8% YoY 19.8% QoQ
2024 110
-73.4% YoY -78.8% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and hematologic malignancies search interestLast update: February 09 2024 08:34:25.
Correlation coefficient between keyword and revenue is -0.54
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 08:34:27.

The average 5 years interest of hematologic malignancies was 29.2 per week.
The last year interest of hematologic malignancies compared to the last 5 years has changed by 0.89%.
The interest for hematologic malignancies is seasonal.
The last year interest is comparable to 5 years ago. It has changed only by 0.65%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 08:34:32.

After 39 days of this quarter the interest is at 312.0. Based on that we can calculate that during remaining 52 days it will total up to 728.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019590
845
43.2% QoQ
776
-8.2% QoQ
794
2.3% QoQ
2020 821
39.2% YoY 3.4% QoQ
721
-14.7% YoY -12.2% QoQ
697
-10.2% YoY -3.3% QoQ
687
-13.5% YoY -1.4% QoQ
2021 724
-11.8% YoY 5.4% QoQ
766
6.2% YoY 5.8% QoQ
750
7.6% YoY -2.1% QoQ
691
0.6% YoY -7.9% QoQ
2022 874
20.7% YoY 26.5% QoQ
849
10.8% YoY -2.9% QoQ
735
-2.0% YoY -13.4% QoQ
817
18.2% YoY 11.2% QoQ
2023 870
-0.5% YoY 6.5% QoQ
866
2.0% YoY -0.5% QoQ
847
15.2% YoY -2.2% QoQ
934
14.3% YoY 10.3% QoQ
2024 312
-64.1% YoY -66.6% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and leukemia treatment search interestLast update: February 09 2024 08:34:31.
Correlation coefficient between keyword and revenue is -0.82
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 08:34:33.

The average 5 years interest of leukemia treatment was 61.17 per week.
The last year interest of leukemia treatment compared to the last 5 years has changed by 9.02%.
The interest for leukemia treatment is relatively stable in the last 5 years.
The last year interest is comparable to 5 years ago. It has changed only by 4.17%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 08:34:36.

After 39 days of this quarter the interest is at 276.0. Based on that we can calculate that during remaining 52 days it will total up to 644.0.
That appears to be equal to previous quarter and same quarter last year.

YearQ1Q2Q3Q4
2019516
815
57.9% QoQ
830
1.8% QoQ
799
-3.7% QoQ
2020 785
52.1% YoY -1.8% QoQ
903
10.8% YoY 15.0% QoQ
847
2.0% YoY -6.2% QoQ
873
9.3% YoY 3.1% QoQ
2021 788
0.4% YoY -9.7% QoQ
847
-6.2% YoY 7.5% QoQ
785
-7.3% YoY -7.3% QoQ
808
-7.4% YoY 2.9% QoQ
2022 905
14.8% YoY 12.0% QoQ
910
7.4% YoY 0.6% QoQ
878
11.8% YoY -3.5% QoQ
880
8.9% YoY 0.2% QoQ
2023 805
-11.0% YoY -8.5% QoQ
845
-7.1% YoY 5.0% QoQ
749
-14.7% YoY -11.4% QoQ
989
12.4% YoY 32.0% QoQ
2024 276
-65.7% YoY -72.1% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and relapse prevention search interestLast update: February 09 2024 08:34:36.
Correlation coefficient between keyword and revenue is 0.33
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 08:34:38.

The average 5 years interest of relapse prevention was 64.49 per week.
The last year interest of relapse prevention compared to the last 5 years has changed by -1.09%.
The interest for relapse prevention is relatively stable in the last 5 years.
The last year interest is comparable to 5 years ago. It has changed only by 1.69%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 08:34:42.

After 39 days of this quarter the interest is at 93.0. Based on that we can calculate that during remaining 52 days it will total up to 217.0.
hematopoietic stem cell transplantation expected interest is significantly lower compared to previous quarter (-52.2%) but similar to same quarter last year.

YearQ1Q2Q3Q4
2019174
468
169.0% QoQ
415
-11.3% QoQ
352
-15.2% QoQ
2020 406
133.3% YoY 15.3% QoQ
300
-35.9% YoY -26.1% QoQ
202
-51.3% YoY -32.7% QoQ
293
-16.8% YoY 45.0% QoQ
2021 290
-28.6% YoY -1.0% QoQ
188
-37.3% YoY -35.2% QoQ
261
29.2% YoY 38.8% QoQ
283
-3.4% YoY 8.4% QoQ
2022 447
54.1% YoY 58.0% QoQ
414
120.2% YoY -7.4% QoQ
200
-23.4% YoY -51.7% QoQ
193
-31.8% YoY -3.5% QoQ
2023 275
-38.5% YoY 42.5% QoQ
395
-4.6% YoY 43.6% QoQ
241
20.5% YoY -39.0% QoQ
454
135.2% YoY 88.4% QoQ
2024 93
-66.2% YoY -79.5% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and hematopoietic stem cell transplantation search interestLast update: February 09 2024 08:34:42.
Correlation coefficient between keyword and revenue is -0.31
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 08:34:43.

The average 5 years interest of hematopoietic stem cell transplantation was 24.31 per week.
The last year interest of hematopoietic stem cell transplantation compared to the last 5 years has changed by 10.9%.
The interest for hematopoietic stem cell transplantation is seasonal.
The last year interest is comparable to 5 years ago. It has changed only by -12.21%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 09:37:29.

After 39 days of this quarter the interest is at 0.0. Based on that we can calculate that during remaining 52 days it will total up to 0.0.
solid tumors treatment expected interest is significantly lower compared to previous quarter (-100.0%) and same quarter last year (-100.0%).

YearQ1Q2Q3Q4
201929
211
627.6% QoQ
223
5.7% QoQ
124
-44.4% QoQ
2020 15
-48.3% YoY -87.9% QoQ
186
-11.8% YoY 1140.0% QoQ
59
-73.5% YoY -68.3% QoQ
96
-22.6% YoY 62.7% QoQ
2021 95
533.3% YoY -1.0% QoQ
89
-52.2% YoY -6.3% QoQ
172
191.5% YoY 93.3% QoQ
152
58.3% YoY -11.6% QoQ
2022 117
23.2% YoY -23.0% QoQ
153
71.9% YoY 30.8% QoQ
99
-42.4% YoY -35.3% QoQ
188
23.7% YoY 89.9% QoQ
2023 70
-40.2% YoY -62.8% QoQ
113
-26.1% YoY 61.4% QoQ
86
-13.1% YoY -23.9% QoQ
182
-3.2% YoY 111.6% QoQ
2024 0
-100.0% YoY -100.0% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and solid tumors treatment search interestLast update: February 09 2024 08:34:46.
Correlation coefficient between keyword and revenue is -0.43
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 09:37:31.

The average 5 years interest of solid tumors treatment was 9.42 per week.
The last year interest of solid tumors treatment compared to the last 5 years has changed by -22.19%.
This is something to be checked.
The last year interest is quite lower compared to 5 years ago. It has decreased by -35.08%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interestLast update: February 09 2024 08:34:54.

After 39 days of this quarter the interest is at 231.0. Based on that we can calculate that during remaining 52 days it will total up to 539.0.
vaccines for infectious diseases expected interest is significantly higher compared to previous quarter (+119.1%) and same quarter last year (+239.0%).

YearQ1Q2Q3Q4
201942
63
50.0% QoQ
83
31.7% QoQ
197
137.3% QoQ
2020 113
169.0% YoY -42.6% QoQ
291
361.9% YoY 157.5% QoQ
151
81.9% YoY -48.1% QoQ
313
58.9% YoY 107.3% QoQ
2021 227
100.9% YoY -27.5% QoQ
170
-41.6% YoY -25.1% QoQ
306
102.6% YoY 80.0% QoQ
74
-76.4% YoY -75.8% QoQ
2022 219
-3.5% YoY 195.9% QoQ
135
-20.6% YoY -38.4% QoQ
90
-70.6% YoY -33.3% QoQ
259
250.0% YoY 187.8% QoQ
2023 159
-27.4% YoY -38.6% QoQ
343
154.1% YoY 115.7% QoQ
233
158.9% YoY -32.1% QoQ
246
-5.0% YoY 5.6% QoQ
2024 231
45.3% YoY -6.1% QoQ
- - -
this symbol represents interest this quarter up to now and updates daily. For expected interest by the end of the quarter based on current trend see "Quarter analysis" above the table.
Correlation between past revenue and vaccines for infectious diseases search interestLast update: February 09 2024 08:34:54.
Correlation coefficient between keyword and revenue is -0.73
Interest value is multiplied to fit the chart properly. Correlation level is represented by Pearson correlation coefficient. Value closer to 1 represents higher level of correlation. Value closer to -1 represents inverted relationship. Value closer to 0 represents no relationship.
Analysis of YoY 5Y Google Trends Last update: February 09 2024 08:34:55.

The average 5 years interest of vaccines for infectious diseases was 15.11 per week.
The last year interest of vaccines for infectious diseases compared to the last 5 years has changed by 54.27%.
This is something to be checked.
The last year interest is quite higher compared to 5 years ago. It has increased by 194.32%.

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Novartis collaboration to provide analysis

Correlation between past revenue and Novartis collaboration search interest

There is not enough data for Novartis collaboration to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Novartis collaboration to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Quarter analysis & expected interest

There is not enough data for Amgen collaboration to provide analysis

Correlation between past revenue and Amgen collaboration search interest

There is not enough data for Amgen collaboration to provide correlation calculation

Analysis of YoY 5Y Google Trends

There is not enough data for Amgen collaboration to provide analysis

Google Trends widget for keyword preview might not work in your browser. If so, try Google Chrome
Useful links and data for TCRX
Earnings date: 2024-03-06 After close
Company name: Tscan Therapeutics Inc
Sector: Professional, Scientific, and Technical Services
Company's website
Hypercharts
Yahoo Finance
MarketWatch
StockTwits
SEC Filings
SwaggyStocks
Latest articles

2026-09-08T15:16:25.552792139Z

Analyst Upgrades
HC Wainwright & Co. Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1

2026-09-03T13:09:08.424987021Z

Analyst Upgrades
Wedbush Downgrades TScan Therapeutics to Neutral, Lowers Price Target to $1

2026-09-02T08:30:00-04:00

Earnings Call Transcripts
TScan Therapeutics Strategic Update Call - TSCAN THERAPEUTICS INC

2026-09-02T08:30:00-04:00

Earnings Call Transcripts
TScan Therapeutics Strategic Update Call - TSCAN THERAPEUTICS INC

2026-09-02T04:00:00-07:00

GlobeNewswire
TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors

2026-08-12T15:25:33.421928826Z

Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on TScan Therapeutics, Maintains $7 Price Target

2026-08-12T04:00:00-07:00

GlobeNewswire
TScan Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

2026-07-29T04:00:00-07:00

GlobeNewswire
TScan Therapeutics Announces First Patient Dosed in Phase 3 ALLOHA-2™, a Pivotal Trial Evaluating TSC-101 in Patients with Heme Malignancies

2026-06-24T04:00:00-07:00

GlobeNewswire
TScan Therapeutics to Participate in the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

2026-06-23T12:20:32.443710566Z

Analyst Upgrades
Wedbush Reiterates Outperform on TScan Therapeutics, Maintains $5 Price Target

2026-06-23T11:43:51.626746601Z

Analyst Upgrades
Needham Reiterates Buy on TScan Therapeutics, Maintains $6 Price Target

2026-06-22T08:30:00-04:00

Earnings Call Transcripts
ALLOHA Cohort C Data Presentation - TScan Therapeutics

2026-06-22T04:00:00-07:00

GlobeNewswire
TScan Therapeutics Announces Positive Initial Data from Cohort C of Ongoing ALLOHA™ Phase 1 Study Evaluating TSC-101 in Patients with Heme Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation

2026-06-03T13:19:00Z

BusinessWire
Cellares and TScan Therapeutics Announce Agreement to Evaluate Automated Manufacturing of TSC-101 for Patients with Hematologic Malignancies

2026-05-06T11:00:00Z

GlobeNewswire
TScan Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update